Anavex President & CEO Christopher U. Missling, PhD, will be presenting preclinical data on ANAVEX 2-73™ at the Epilepsy Foundation’s Antiepileptic Drug Trials XIV Conference on May 19, 2017.
May 17-19, 2017 | Turnberry Isle Miami Hotel | Aventura, Florida
Antiepileptic Drug Trials XIV Conference | May 2017
Friday, May 19, 2017
ANAVEX 2-73, A Clinical Candidate for Neurodevelopmental Disorders
Christopher Missling, PhD, Anavex Life Sciences Corp.